These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 16355548)

  • 41. Comparison of the therapeutic effects of epoetin zeta to epoetin alfa in the maintenance phase of renal anaemia treatment.
    Wizemann V; Rutkowski B; Baldamus C; Scigalla P; Koytchev R;
    Curr Med Res Opin; 2008 Mar; 24(3):625-37. PubMed ID: 18208642
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The cost-effectiveness of weekly epoetin alfa relative to weekly darbepoetin alfa in patients with chemotherapy-induced anemia.
    Ben-Hamadi R; Duh MS; Aggarwal J; Henckler A; McKenzie RS; Tak Piech C
    Curr Med Res Opin; 2005 Oct; 21(10):1677-82. PubMed ID: 16238908
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Comments on Clinical and economic comparison of epoetin alfa and darbepoetin alfa.
    Sullivan SD
    Curr Med Res Opin; 2004 Sep; 20(9):1461; author reply 1462-3. PubMed ID: 15487107
    [No Abstract]   [Full Text] [Related]  

  • 44. Darbepoetin alfa and chronic kidney disease.
    Locatelli F; Del Vecchio L; Casartelli D
    N Engl J Med; 2010 Feb; 362(7):654-5; author reply 655. PubMed ID: 20187259
    [No Abstract]   [Full Text] [Related]  

  • 45. Darbepoetin alpha is highly cost-effective compared with epoetin alpha in the treatment of renal anemia: a brief report from a hemodialysis clinic in Japan.
    Nakagawa T
    Ther Apher Dial; 2008 Dec; 12(6):531-2. PubMed ID: 19140854
    [No Abstract]   [Full Text] [Related]  

  • 46. Use of darbepoetin alfa and epoetin alfa in clinical practice in patients with cancer-related anemia.
    Berger A; Edelsberg J; Kallich J; Oster G
    Clin Ther; 2008 Jan; 30(1):206-18. PubMed ID: 18343258
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Budget impact analysis of darbepoetin alfa every 3 weeks versus epoetin alfa every week for the treatment of chemotherapy-induced anaemia from a US payer's perspective.
    Rubin RJ; Glaspy JA; Adams JL; Mafilios MS; Wang SM; Viswanathan HN; Kallich JD
    J Med Econ; 2008; 11(2):199-213. PubMed ID: 19450080
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Darbepoetin alfa in the treatment of anemia in cancer patients undergoing chemotherapy.
    Wauters I; Vansteenkiste J
    Expert Rev Anticancer Ther; 2012 Nov; 12(11):1383-90. PubMed ID: 23113603
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Comparative studies on erythropoietic agents.
    Straus D
    J Natl Compr Canc Netw; 2005 Nov; 3 Suppl 1():S46-9. PubMed ID: 16280113
    [No Abstract]   [Full Text] [Related]  

  • 50. Hemoglobin stability in patients with anemia, CKD, and type 2 diabetes: an analysis of the TREAT (Trial to Reduce Cardiovascular Events With Aranesp Therapy) placebo arm.
    Skali H; Lin J; Pfeffer MA; Chen CY; Cooper ME; McMurray JJ; Nissenson AR; Remuzzi G; Rossert J; Parfrey PS; Scott-Douglas NW; Singh AK; Toto R; Uno H; Ivanovich P
    Am J Kidney Dis; 2013 Feb; 61(2):238-46. PubMed ID: 23159232
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Treating anemia of cancer with every-4-week darbepoetin alfa: final efficacy and safety results from a phase II, randomized, double-blind, placebo-controlled study.
    Gordon D; Nichols G; Ben-Jacob A; Tomita D; Lillie T; Miller C
    Oncologist; 2008 Jun; 13(6):715-24. PubMed ID: 18586927
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effectiveness of weekly darbepoetin alfa in the treatment of anaemia of HIV-infected haemodialysis patients.
    Lucas C; Carrera F; Jorge C; Boquinhas H; Pais MJ
    Nephrol Dial Transplant; 2006 Nov; 21(11):3202-6. PubMed ID: 16891651
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Darbepoetin alfa: a new approach to the treatment of chemotherapy-induced anaemia.
    Vansteenkiste J; Rossi G; Foote M
    Expert Opin Biol Ther; 2003 Jun; 3(3):501-8. PubMed ID: 12783618
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Health economic evaluation of treating anemia in cancer patients receiving chemotherapy: a study in Belgian hospitals.
    Spaepen E; Demarteau N; Van Belle S; Annemans L
    Oncologist; 2008 May; 13(5):596-607. PubMed ID: 18515745
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Darbepoetin alfa and chronic kidney disease.
    Wright RJ; Kanagasundaram NS; Quinton R
    N Engl J Med; 2010 Feb; 362(7):653; author reply 655. PubMed ID: 20164489
    [No Abstract]   [Full Text] [Related]  

  • 56. A US multicenter, retrospective, observational study of erythropoiesis-stimulating agent utilization in anemic, critically ill patients admitted to the intensive care unit.
    Brophy GM; Sheehan V; Shapiro MJ; Lottenberg L; Scarlata D; Audhya P;
    Clin Ther; 2008 Dec; 30(12):2324-34. PubMed ID: 19167591
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Serum hepcidin levels predict response to intravenous iron and darbepoetin in chemotherapy-associated anemia.
    Steensma DP; Sasu BJ; Sloan JA; Tomita DK; Loprinzi CL
    Blood; 2015 Jun; 125(23):3669-71. PubMed ID: 26045598
    [No Abstract]   [Full Text] [Related]  

  • 58. Erythropoiesis-stimulating agents in the treatment of cancer-associated anemia.
    Bohlius J; Engert A; Schwarzer G
    JAMA; 2008 Dec; 300(24):2854-5; author reply 2855-7. PubMed ID: 19109112
    [No Abstract]   [Full Text] [Related]  

  • 59. Retrospective observational study of patients with chemotherapy-related anemia receiving erythropoietic agents.
    Mark TL; McKenzie RS; Fastenau J; Piech CT
    Curr Med Res Opin; 2005 Sep; 21(9):1347-54. PubMed ID: 16197652
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Effects of darbepoetin alfa administered every two weeks on hemoglobin and quality of life of patients receiving chemotherapy.
    Folloder J
    Oncol Nurs Forum; 2005 Jan; 32(1):81-91. PubMed ID: 15660146
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.